Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.59 |
| ▸ | PI4KA | P42356 | 2/20 | 0.47 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.47 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | CDK1 | P06493 | 9/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 9/20 | 0.46 |
| ▸ | CDK2 | P24941 | 9/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
| ▸ | PNP | P00491 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592683 | 1.00 | PDPK1 (0.59) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Water SCHEMBL28083708 | 0.98 | PDPK1 (0.58) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29514836 | 0.86 | PDPK1 (0.56) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL215054 | 0.86 | PDPK1 (0.56) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL11222102 | 0.85 | PDPK1 (0.63) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| Barbital SCHEMBL2130352 | 0.85 | PDPK1 (0.44) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL17060283 | 0.84 | PDPK1 (0.61) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL1074970 | 0.83 | POLA1 (0.57) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL28299226 | 0.82 | POLA1 (0.53) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL9176120 | 0.82 | PDPK1 (0.59) | PDPK1GDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103833915-B | Molecularly imprinted polymer nano particle suitable for pure biological sample and preparation method thereof | 南开大学 | 2018-04-13 | — | — | CN | claimed |
| CN-104447746-A | Compound for activating AMPK and application thereof | HUAAN MEDICAL CO LTD | 2015-03-25 | — | — | CN | claimed |
| CN-103822988-B | Application of LC (liquid chromatogram) tandem mass spectrum method in biological monitoring of N3-(2-hydroxyethyl)-adenine in large-scale smoker crowd samples | NAT TOBACCO QUALITY SUPERVISION & INSPECTION CT | 2015-01-07 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| WO-2026089806-A2 | SAA1-TARGETED OLIGOMERIC COMPOUNDS, COMPOSITIONS AND USES | N-LOREM FOUNDATION (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4499281-A1 | BARRIERS INCLUDING CROSS-LINKED AMPHIPHILIC MOLECULES, AND METHODS OF MAKING THE SAME | Illumina, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4499278-A1 | BARRIERS INCLUDING BIOLOGICAL NANOPORE FOR DNA SEQUENCING, THE BARRIERS BEING MADE OF CO-POLYMERS WITH END AND/OR MIDDLE GROUPS, AND METHODS OF MAKING THE SAME | ILLUMINA, INC. (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4405502-A1 | SEQUENCING POLYNUCLEOTIDES USING NANOPORES | Illumina, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024081163-A1 | METHOD OF TREATING LBSL BY MODULATING DARS2 | THE JOHNS HOPKINS UNIVERSITY (US) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024068997-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023229884-A2 | 3'-BLOCKED NUCLEOTIDES, METHODS OF DEBLOCKING THE SAME, AND METHODS OF SYNTHESIZING POLYNUCLEOTIDES USING THE SAME | ILLUMINA, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023187104-A1 | NANOPORE DEVICES INCLUDING BARRIERS USING DIBLOCK OR TRIBLOCK COPOLYMERS, AND METHODS OF MAKING THE SAME | ILLUMINA CAMBRIDGE LIMITED (GB) | 2023-10-05 | — | — | WO | disclosed |
| CN-1242373-A | Novel arabinosyladenine derivatives | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2000-01-26 | — | — | CN | disclosed |
| CN-1232466-A | Phosphonate-nucleotide compounds | MITSUBISHI CHEM CORP (JP) | 1999-10-20 | — | — | CN | disclosed |
| WO-1999036575-A1 | MULTIPLEX VGID | VALIGENE CORPORATION (US) | 1999-07-22 | — | — | WO | disclosed |
| CN-1040761-C | Fused nitrogenous heterocyclic derivatives containing ethyl phosphonate side chain, pharmaceutical compositions containing them and their use | MITSUBISHI CHEM IND (JP) | 1998-11-18 | — | — | CN | disclosed |
| WO-1998007736-A1 | DON-1 GENE AND POLYPEPTIDES AND USES THEREFOR | MILLENNIUM BIOTHERAPEUTICS, INC. (US) | 1998-02-26 | — | — | WO | disclosed |
| CN-1164534-A | Phosphonate nucleotide compounds | MITSUBISHI CHEM CORP (JP) | 1997-11-12 | — | — | CN | disclosed |
| CN-1106017-A | Phosphonate nucleotide derivatives | MITSUBISHI CHEM IND (JP) | 1995-08-02 | — | — | CN | disclosed |
| CN-1100302-A | Inhibition and treatment of infection by enveloped virus with calix(n)arene compounds | GENELABS TECH INC (US) | 1995-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | PDPK1 281/4885GDA 1170/4885PI4KA 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.